Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice.
Giulia BonaldoNicola Montanaronull AlbertoVaccheriDomenico MotolaPublished in: European journal of clinical pharmacology (2021)
CRS represents the major problem with the administration of CAR-T therapies. Our analysis has not revealed new ADRs; however, it supports the safety profile of CAR-T with new data from real clinical setting.